Home » Stocks » Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc. (IRWD)

Stock Price: $10.18 USD -0.03 (-0.25%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $10.18 +0.01 (0.05%) Aug 10, 4:41 PM

Stock Price Chart

Key Info

Market Cap 1.63B
Revenue (ttm) 426.84M
Net Income (ttm) 97.06M
Shares Out 159.38M
EPS (ttm) 0.62
PE Ratio 16.41
Forward PE 22.08
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $10.18
Previous Close $10.20
Change ($) -0.03
Change (%) -0.25%
Day's Open 10.28
Day's Range 10.17 - 10.43
Day's Volume 1,854,092
52-Week Range 7.91 - 14.10

More Stats

Market Cap 1.63B
Enterprise Value 1.83B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 159.38M
Float 141.67M
EPS (basic) 0.62
EPS (diluted) 0.62
FCF / Share 0.74
Dividend n/a
Dividend Yield n/a
Earnings Yield 6.09%
FCF Yield 7.28%
Payout Ratio n/a
Shares Short 26.56M
Short Ratio 14.17
Short % of Float 24.41%
Beta 1.31
PE Ratio 16.41
Forward PE 22.08
P/FCF Ratio 13.74
PS Ratio 3.81
PB Ratio n/a
Revenue 426.84M
Operating Income 161.42M
Net Income 97.06M
Free Cash Flow 118.49M
Net Cash -201.20M
Net Cash / Share -1.26
Gross Margin 68.65%
Operating Margin 37.82%
Profit Margin 22.70%
FCF Margin 27.76%
ROA 26.94%
ROE n/a
ROIC 21.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 2
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$12.33*
(21.18% upside)
Low
11.0
Current: $10.18
High
14.0
Target: 12.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue42834729827415076.4422.8815065.8743.86
Revenue Growth23.59%16.21%8.88%83.18%95.66%234.06%-84.77%128.09%50.19%-
Gross Profit40831427927213250.8515.6814965.8743.86
Operating Income120-182-46.67-42.04-102-169-252-72.76-66.14-60.77
Net Income21.51-282-117-81.71-143-190-273-72.62-64.85-52.98
Shares Outstanding15615314914514213711610699.8889.65
Earnings Per Share0.14-1.85-0.78-0.56-1.00-1.39-2.35-0.68-0.65-0.59
Dividend Per Share2.29---------
Operating Cash Flow10.73-70.88-101-25.93-107-156-273-69.63-75.24-67.90
Capital Expenditures-6.921.21-2.67-3.98-3.90-3.54-9.59-13.97-9.68-17.22
Free Cash Flow3.80-69.67-103-29.92-111-159-283-83.60-84.92-85.12
Cash & Equivalents178174221313448256206176172259
Total Debt4554484924864571731790.570.660.59
Net Cash / Debt-277-273-271-173-8.6783.3526.80175171258
Assets403332606710619329279230209301
Liabilities49652859664352424124185.8699.12142
Book Value-93.25-1969.8566.7295.1388.5538.23144110160
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ironwood Pharmaceuticals, Inc.
Country United States
Employees 317
CEO Mark Mallon

Stock Information

Ticker Symbol IRWD
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: IRWD
IPO Date February 3, 2010

Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.